Market closed

Elanco/$ELAN

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Elanco

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Ticker

$ELAN

Sector

Health Care

Trading on

NYSE

Industry

Pharmaceuticals

Headquarters

Greenfield, United States

Employees

9,550

Website

www.elanco.com

Elanco Metrics

BasicAdvanced

$5.8B

28.36 $0.41

1.42 -

Price and volume

Market cap

$5.8B

Beta

1.42

52-week high

$18.80

52-week low

$11.11

Average daily volume

4.5M

Financial strength

Current ratio

2.548

Quick ratio

1.055

Long term debt to equity

66.12

Total debt to equity

66.794

Interest coverage (TTM)

1.02%

Management effectiveness

Return on assets (TTM)

1.18%

Return on equity (TTM)

3.24%

Valuation

Price to earnings (TTM)

28.355

Price to revenue (TTM)

1.297

Price to book

0.89

Price to tangible book (TTM)

-2.74

Price to free cash flow (TTM)

15.526

Growth

Revenue change (TTM)

1.99%

Earnings per share change (TTM)

-117.72%

3-year revenue growth (CAGR)

-2.40%

3-year earnings per share growth (CAGR)

-33.98%

What the Analysts think about Elanco

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Elanco stock.

Elanco Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Elanco Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Elanco News

AllArticlesVideos

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect

Accesswire·3 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation

Accesswire·1 week ago

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation

Accesswire·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ELAN

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Elanco stock?

Elanco (ELAN) has a market cap of $5.8B as of January 15, 2025.

What is the P/E ratio for Elanco stock?

The price to earnings (P/E) ratio for Elanco (ELAN) stock is 28.36 as of January 15, 2025.

Does Elanco stock pay dividends?

No, Elanco (ELAN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Elanco dividend payment date?

Elanco (ELAN) stock does not pay dividends to its shareholders.

What is the beta indicator for Elanco?

Elanco (ELAN) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.